Glioblastoma

Malignant gliomas, particularly glioblastoma multiforme (GBM) are the most frequent primary malignant brain tumors in adults and associated with a very poor prognosis. Although GBM is a rare tumor with an incidence of 3.23 cases per 100,000 individuals per year worldwide, it is still a deadly disease with a long term survival beyond 5 years of only 6.8%.¹ Patients typically have a median overall survival of 19.2-23.8 months from diagnosis.^2,3

More than 250,000 new cases of primary malignant brain tumors are diagnosed annually worldwide, 77% of which are gliomas.³

References

1. Pellerino, A., Caccese, M., Padovan, M. et al. Epidemiology, risk factors, and prognostic factors of gliomas. Clin Transl Imaging 10, 467–475 (2022).
2. Tesileanu CMS, Dirven L, Wijnenga MMJ et al (2020) Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol 22(4):515–523.
3. Walsh KM, Ohgaki H, Wrensch MR. Epidemiology. Handb Clin Neurol. 2016;134:3-18. doi: 10.1016/B978-0-12-802997-8.00001-3. PMID: 26948345.